Effect of Renamezin upon attenuation of renal function decline in pre-dialysis chronic kidney disease patients: 24-week prospective observational cohort studyopen access
- Authors
- Park, Hayne Cho; Cho, Ajin; Kim, Do Hyoung; Yun, Kyu-Sang; Kim, Juhee; Lee, Eun Young; Jo, Sang Kyung; Lee, So-Young; Han, Kum Hyun; Chang, Yoon Kyung; Oh, Dong-Jin; Lee, Young-Ki
- Issue Date
- Jun-2021
- Publisher
- Public Library of Science
- Citation
- PLoS ONE, v.16, no.6 , pp.1 - 12
- Indexed
- SCIE
SCOPUS
- Journal Title
- PLoS ONE
- Volume
- 16
- Number
- 6
- Start Page
- 1
- End Page
- 12
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/141785
- DOI
- 10.1371/journal.pone.0252186
- ISSN
- 1932-6203
- Abstract
- Renamezin® is a modified capsule-type oral spherical adsorptive carbon which lowers indoxyl sulfate levels in patients with advanced chronic kidney disease (CKD). This 24-week prospective observational cohort study was performed to evaluate the effect of Renamezin® upon attenuation of renal function decline. A total of 1,149 adult patients with baseline serum creatinine 2.0-5.0 mg/dL were enrolled from 22 tertiary hospital in Korea from April 2016 to September 2018. Among them, a total of 686 patients completed the study and were included in the intention-to-treat analysis. A total of 1,061 patients were included in the safety analysis. The mean age was 63.5 years and male patients were predominant (63.6%). Most of the patients (76.8%) demonstrated high compliance with study drug (6g per day). After 24 week of treatment, serum creatinine was increased from 2.86±0.72 mg/dL to 3.06±1.15 mg/dL (p<0.001), but estimated glomerular filtration rate was not changed significantly during observation period (22.3±6.8 mL/min/1.73m2to 22.1±9.1 mL/min/1.73m2, p = 0.243). Patients with age over 65 years old and those under good systolic blood pressure control <130 mmHg were most likely to get benefit from Renamezin® treatment to preserve renal function. A total of 98 (9.2%) patients out of 1,061 safety population experienced 134 adverse events, of which gastrointestinal disorders were the most common. There were no serious treatment-related adverse events. Renamezin® can be used safely to attenuate renal function decline in moderately advanced CKD patients.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 교육협력지원교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/141785)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.